Combining a vaccine and T cell therapy to treat uveal melanoma
Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy
This study is testing a new way to treat metastatic uveal melanoma by using a special vaccine and a personalized T cell therapy to help your immune system fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10669241 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for metastatic uveal melanoma by combining a specialized vaccine with adoptive T cell therapy. Patients will receive a tailored T cell product that targets a specific protein (PRAME) found in their tumors, along with a vaccine made from synthetic peptides designed to enhance the immune response. Additionally, an immune checkpoint inhibitor will be used to improve the effectiveness of the treatment by modifying the tumor environment. This innovative combination aims to improve patient outcomes by sustaining the activity of the immune cells against the cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with metastatic uveal melanoma who have not responded adequately to existing treatments.
Not a fit: Patients with non-melanoma cancers or those who have not been diagnosed with metastatic uveal melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with metastatic uveal melanoma.
How similar studies have performed: Previous research has shown promise in combining immunotherapy approaches, suggesting potential for success with this novel treatment strategy.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Yee, Cassian — University of Tx Md Anderson Can Ctr
- Study coordinator: Yee, Cassian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.